← Back to Search

Beta Blocker

Behavioral + Propranolol for Misophonia (Miso Prop Trial)

Phase < 1
Waitlist Available
Led By Daniela Schiller, PhD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and after 6 hours

Summary

This trial is testing whether propranolol can help people with misophonia, a condition where certain sounds cause strong negative reactions. The medication aims to weaken the bad memories associated with these sounds. By doing so, it might make these sounds less distressing for those affected. Propranolol has been used in various psychiatric treatments and has shown potential in reducing anxiety and improving cognitive functions.

Who is the study for?
This trial is for adults aged 18-55 with misophonia, which means they have strong negative reactions to certain sounds. Participants must speak English fluently and not be pregnant, breastfeeding, or have a pulse outside of the range 55-100 bpm. They should not take specific medications that interact with propranolol, have high or low blood pressure issues, cardiovascular illnesses, respiratory diseases like COPD, diabetes mellitus, CNS diseases or recent drug abuse.
What is being tested?
The study tests if interfering with memory reconsolidation using propranolol can reduce aversive reactions in misophonia when reminded of triggering sounds. It compares this approach against placebo and counterconditioning techniques through behavioral and neural analyses.
What are the potential side effects?
Propranolol may cause side effects such as dizziness, fatigue, trouble sleeping, stomach cramps and nausea. In some cases it might also affect heart rate and blood pressure or worsen breathing problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and after 6 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and after 6 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in average Galvanic skin response based on deflections of a wave
Secondary study objectives
Change in Approach-Avoidance test
Change in Average Galvanic skin response based on deflections of a wave
Change in average heart rate
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: No memory reminder followed by counterconditioningExperimental Treatment1 Intervention
This arm aims to have 30 participants with a behavioral manipulation. They will not receive a reminder to reactivate their memory of a misophonia trigger and then undergo counterconditioning.
Group II: No memory reminder followed by Propranolol HydrochlorideExperimental Treatment1 Intervention
This arm aims to have 30 participants with a pharmacological manipulation. They will not receive a reminder to reactivate their memory of a misophonia sound and only receive a propranolol hydrochloride tablet.
Group III: Memory reminder followed by counterconditioningExperimental Treatment2 Interventions
This arm aims to have 30 participants with a behavioral manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger and then will undergo counterconditioning.
Group IV: Memory Reminder followed by Propranolol HydrochlorideExperimental Treatment2 Interventions
This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a propranolol hydrochloride tablet.
Group V: Memory reminder followed by PlaceboPlacebo Group2 Interventions
This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a placebo tablet.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Counterconditioning
2023
Completed Early Phase 1
~290
Propranolol Hydrochloride tablet
2023
Completed Early Phase 1
~150
Reminder
2023
Completed Early Phase 1
~311310

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Misophonia often target the associative learning and memory processes that underlie the condition. Propranolol, a beta-blocker, is being studied for its ability to interfere with the reconsolidation of reactivated misophonia memories. By disrupting the emotional learning and memory processes that reinforce negative responses to specific sounds, propranolol may alleviate the aversive reactions associated with Misophonia. This approach is significant for patients as it offers a targeted method to modify the neural pathways responsible for their condition, potentially leading to more effective and lasting relief.
Chronic propranolol induces deficits in retention but not acquisition performance in the water maze in mice.

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
909 Previous Clinical Trials
542,019 Total Patients Enrolled
Daniela Schiller, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
Laili Soleimani, MD, MscPrincipal InvestigatorIcahn School of Medicine at Mount Sinai

Media Library

Propranolol Hydrochloride (Beta Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05928689 — Phase < 1
Misophonia Research Study Groups: No memory reminder followed by Propranolol Hydrochloride, Memory reminder followed by Placebo, Memory Reminder followed by Propranolol Hydrochloride, No memory reminder followed by counterconditioning, Memory reminder followed by counterconditioning
Misophonia Clinical Trial 2023: Propranolol Hydrochloride Highlights & Side Effects. Trial Name: NCT05928689 — Phase < 1
Propranolol Hydrochloride (Beta Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05928689 — Phase < 1
~56 spots leftby Dec 2025